Skip to main content
OpenTrials
Completed

NCT Number: NCT00730782

Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers

The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or AS02A or Montanide ISA 720 in healthy adults not previously exposed to the parasite Plasmodium falciparum.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 and < 45 years healthy volunteers.
  • General good health based on history and clinical examination.
  • All volunteers have to sign the informed consent form.
  • Negative pregnancy test.
  • Use of adequate contraception for females up to three months after the third injection (D140).
  • Reachable by phone during the whole study period (18 months).

Exclusion criteria

  • History of malaria or residence in malaria endemic areas within the past six months.
  • Positive serology for malaria antigen PfAMA-1
  • Previously participated in any malaria vaccine study
  • Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers.
  • Any laboratory abnormalities on screened blood samples beyond the normal range, as defined at UMC St Radboud. Positive HIV, HBV or HCV tests.
  • Volunteers should not be enrolled in any other clinical trial during the whole trial period.
  • Volunteers should not receive chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the three months preceding the screening visit or during the study period.
  • Pregnant or lactating women.
  • Volunteers unable to give written informed consent.
  • Volunteers unable to be closely followed for social, geographic or psychological reasons.
  • Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrollment in the study.
  • Volunteers should not perform exercise four hours before blood draw and should not donate blood for non study-related purposes during the entire duration of the study.
  • Known hypersensitivity to any of the vaccine components (adjuvant or peptide).
  • Volunteers are not allowed to receive any vaccination or gammaglobulin during a period three months prior to the first immunization and up to six months after the 3rd immunization. If a vaccination is necessary during this period, the volunteer will be withdrawn from the study.
  • Volunteers are not allowed to travel to malaria endemic countries during the study period.

Treatment and study plan

PfAMA-1-FVO[25-545]

Biological

Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1

Primary outcomes

  1. Local and systemic reactogenicity

    Time frame: Day 0-14 after each vaccination

Secondary outcomes

  1. Biological Safety

    Time frame: 28 days after each vaccination

  2. Humoral and Cellular immunogenicity

    Time frame: until 365 days after the first immunisation

Sponsors and collaborators

Lead sponsor

European Vaccine Initiative

Other

Collaborators

  • Biomedical Primate Research Centre
  • GlaxoSmithKline
  • Radboud University Medical Center
  • Seppic

Registry information

Official study title

Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial

Important dates

Study start
2005
Primary completion
2007
Study completion
2008
First posted
Aug 8, 2008
Registry last updated
Aug 8, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.